U.S. Physical Therapy, Inc.

U.S. Physical Therapy, Inc. (USPH) Market Cap

U.S. Physical Therapy, Inc. has a market capitalization of $1.14B.

Financials based on reported quarter end 2025-12-31

Price: $75.17

-0.34 (-0.46%)

Market Cap: 1.14B

NYSE · time unavailable

CEO: Christopher J. Reading

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1992-05-29

Website: https://www.usph.com

U.S. Physical Therapy, Inc. (USPH) - Company Information

Market Cap: 1.14B · Sector: Healthcare

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2021, it operated 591 clinics in 39 states; and managed 35 physical therapy practice facilities. The company was founded in 1990 and is based in Houston, Texas.

Analyst Sentiment

75%
Strong Buy

Based on 12 ratings

Analyst 1Y Forecast: $102.00

Average target (based on 2 sources)

Consensus Price Target

Low

$102

Median

$102

High

$102

Average

$102

Potential Upside: 35.7%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 US PHYSICAL THERAPY INC (USPH) — Investment Overview

🧩 Business Model Overview

US Physical Therapy, Inc. (USPH) operates as one of the largest pure-play providers of outpatient physical therapy services in the United States. The company primarily manages, acquires, and operates outpatient physical therapy clinics as well as select industrial injury prevention businesses. USPH partners with rehabilitation professionals and clinic managers through a clinic partnership model, typically owning a majority interest while aligning incentives with local therapists via minority equity stakes in each clinic. This decentralized, partnership-driven structure underpins both operational efficiency and strategic clinic expansion nationwide. USPH’s business model emphasizes organic same-clinic growth supplemented by disciplined M&A activity, leveraging its proven management platform to integrate acquisitions seamlessly.

💰 Revenue Streams & Monetisation Model

USPH generates revenue predominantly from patient care services rendered in its network of outpatient physical therapy clinics. Revenue is derived through fee-for-service arrangements, contracted rates with commercial insurers, government payors (such as Medicare), worker’s compensation programs, and, to a lesser extent, cash-paying patients. The company also earns income from value-added services in the industrial injury prevention segment, which includes onsite injury prevention, ergonomic assessments, and wellness services delivered to employer clients. Ancillary revenue streams may include occupational therapy, speech therapy, and occasionally from management and consulting arrangements. The diversity of USPH’s payer mix, with a significant share from commercial insurance, helps buffer the company against fluctuations within any single reimbursement channel.

🧠 Competitive Advantages & Market Positioning

USPH benefits from a range of competitive strengths that support its robust market positioning. The company’s decentralized partnership model fosters local clinician-ownership, which improves patient engagement, clinic accountability, and talent retention. An established acquisition platform allows USPH to identify, integrate, and grow independent clinics that often lack scale or back-office expertise. Segment focus on outpatient rehabilitation allows USPH to remain nimble compared to hospital-based systems weighed down by higher fixed costs. The company’s geographic footprint covers both suburban and urban markets with room for continued expansion. Reputation for clinical outcomes, recurring patient referrals, and strong relationships with physicians further undergird competitive differentiation. USPH’s scale advantages in procurement, regulatory compliance, and payer contracting enhance margins relative to smaller peers.

🚀 Multi-Year Growth Drivers

Several secular trends and internal initiatives position USPH for sustained multi-year growth. Demographic tailwinds from an aging U.S. population drive increased demand for physical rehabilitation and musculoskeletal care. Rising awareness of non-invasive therapy as an alternative to surgery or opioids further expands addressable demand. Payer focus on lower-cost outpatient settings draws more volume away from hospitals to specialized clinics such as those operated by USPH. The company’s M&A playbook enables inorganic growth in fragmented regional markets by bringing independent clinics into its network. Expansion into adjacent industrial injury prevention amplifies cross-selling opportunities and diversifies the revenue base. Adoption of digital health solutions and tele-rehabilitation extends USPH’s reach and increases patient access, while operational efficiencies realized through technology investments support scalable, margin-accretive growth.

⚠ Risk Factors to Monitor

Investors should remain cognizant of several key risk factors. Changes in government and commercial reimbursement rates—particularly any material reductions in Medicare or insurer payments—could pressure margins and revenue growth. Regulatory shifts, including modifications to CMS coverage policies or state-level licensing requirements, present compliance risks. Talent acquisition and retention remain challenges in a healthcare staffing environment marked by shortages and wage inflation. The competitive landscape features not only independent clinics but also increasing encroachment from hospital systems and national rehabilitation chains. Execution risks tied to acquisitions—such as integration hurdles or overpaying for targets—may impede expected synergies. Furthermore, macroeconomic downturns could dampen elective procedure volumes, reducing referral flow to physical therapy. Finally, potential liability exposures from adverse patient outcomes or worker injuries in the industrial segment warrant attention.

📊 Valuation & Market View

USPH’s valuation reflects its status as a differentiated provider in an essential, largely recession-resistant segment of the healthcare market. The company traditionally trades at a premium to many healthcare service peers, underpinned by superior same-clinic sales growth, attractive EBITDA margins, and high cash flow conversion. The recurring and predictable nature of therapy services, combined with a robust M&A pipeline, supports a growth-oriented multiple. Nonetheless, valuation may be sensitive to evolving reimbursement dynamics and broader health policy changes. Shared consolidation themes with other outpatient healthcare models contribute to favorable investor sentiment, while USPH’s M&A cadence is scrutinized for discipline and value creation.

🔍 Investment Takeaway

US Physical Therapy, Inc. represents a compelling way to gain exposure to the growing outpatient rehabilitation market in the United States. Anchored by its clinician-led partnership model, scalable operating platform, and proven acquisition capability, USPH is well-positioned to benefit from secular healthcare shifts toward outpatient care and preventive medicine. The diversified payer mix and expansion into industrial injury prevention services offer added resilience. While certain risks are inherent in reimbursement, staffing, and regulatory environments, the company’s strong historical execution and disciplined capital allocation underpin a solid investment thesis for long-term-oriented investors seeking stable and growing returns in healthcare services.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"USPH reported revenue of $202.73M for the year ended December 31, 2025, yet posted a net loss of $10.55M, reflecting profitability challenges. The company has total assets of $1.20B and total liabilities of $433.81M, suggesting a solid equity position of $769.74M. Operating cash flow stood at $24.93M, with a free cash flow of $21.01M, indicating healthy cash generation despite the net loss. However, the decline in share price, with a 1.43% increase year-over-year and negative year-to-date performance of -5.30%, raises concerns about shareholder returns, predominantly driven by minimal appreciation and dividends totaling $1.82 per share in 2025. Overall, USPH maintains a robust balance sheet with net debt of $390.17M, allowing room for growth. The consensus price target remains at $102. While revenue growth is promising, ongoing losses may impact long-term sustainability unless addressed."

Revenue Growth

Neutral

Revenue of $202.73M reflects moderate growth potential.

Profitability

Neutral

Net income is negative at -$10.55M, indicating profitability issues.

Cash Flow Quality

Positive

Solid operating cash flow and free cash flow show good cash generation.

Leverage & Balance Sheet

Positive

Healthy equity position with net debt manageable at $390.17M.

Shareholder Returns

Caution

Minimal share price appreciation and moderate dividends; overall returns are subdued.

Analyst Sentiment & Valuation

Neutral

Stable price target of $102 indicates optimism on valuation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management presented a bullish quarter on volume, margin, and guidance, emphasizing record visits per clinic per day (32.7 vs 30.6) and expanding EBITDA margin (17.5% vs 16.4%). They also quantified a major drag from Medicare: stacked cuts impact roughly $25M off the profit line and $5M–$6M vs prior year, yet still raised full-year adjusted EBITDA to $93M–$97M. In the Q&A, however, analyst pressure quickly shifted to the quality of same-store and labor execution. Management confirmed “some markets” remain staffing-tight and same-store growth was “a little lighter” than normal, while cost control created a demand vs. capacity “push-pull.” On 2026, they offered only a preliminary net benefit (1%–1.75% rate increase; ~$2M–$3M top-line; ~$1.5M–$2.5M EBITDA), not a true fix to the historical Medicare hole—highlighting the continued uncertainty around CMS and the need for a multi-year solution. Overall: strong operational momentum, but still constrained by Medicare and localized labor bottlenecks.

AI IconGrowth Catalysts

  • Physical therapy visits per clinic per day hit 32.7 (vs 30.6 prior-year Q2), record Q2
  • Physical therapy revenues up 17.3% to $168.3M (major driver: Metro acquisition in NY, $19.6M of $24.8M growth)
  • IIP (industrial injury prevention) net revenues up 22.6% to $5.3M increase; IIP gross profit up 21.8% (organic)
  • IIP adjusted EBITDA margin expanded to 22% (vs 21.4% prior-year Q2)
  • Home care visits added (28,493 Q2; first time reported separately) from Metro PT acquisition

Business Development

  • Industrial injury prevention partnerships “both are firing on all cylinders” and adding “very large” opportunities, including auto-industry wins (several new, one large + one very large later in the year)
  • Metro PT transaction in New York (acquired home care business; also cited as part of margin adjustments/incentive payment)
  • State-level payer change: largest Michigan payer (56 clinics) policy change effective April 1

AI IconFinancial Highlights

  • Adjusted EBITDA: $26.9M in Q2 2025, up $4.7M YoY; adjusted EBITDA margin 17.5% (vs 16.4%)
  • Physical therapy margin improved to 21.1% (vs 20.1% prior-year Q2); described as a “nice move forward” with only minor adjusted gross profit distortion from an incentive payment related to Metro deal closing
  • Total PT operating cost per visit down YoY even though salaries up only 0.7% YoY (salary/cost per visit $60.08)
  • Physical therapy net rate per visit: $105.33 (vs $105.05 prior-year Q2; vs $105.66 Q1)
  • Medicare rate reduction headwind: 2.9% absorbed at start of year; management quantifies Medicare cuts impact ~ $25M straight off profit line (stacked cuts) and $5M–$6M vs prior year in-year
  • Net rate headwind from Michigan payer: policy change April 1 reduced net rate “a little bit”
  • Full-year guidance raised: adjusted EBITDA range increased to $93M–$97M (from prior $88M–$93M), with $4M increase at the top; high end of prior range becomes low end of new range

AI IconCapital Funding

  • Cash: $34.1M at quarter end
  • Term loan: $135.0M fixed via swap at 4.7% interest through mid-2027
  • Revolver: $175.0M facility with $245.0M drawn at 06/30/2025 (as disclosed)
  • Share repurchase authorization: up to $25.0M through 12/31/2026 (new program; acquisitions remain primary capital priority)

AI IconStrategy & Ops

  • Enterprise-wide financial + HR system implementation in early stages; implementation costs through 2026; $221k incurred YTD; full implementation starts Q3
  • Cash-based programs: staged rollout in spring; generating ~$900k additional revenue (not via additional visits; ramping)
  • Operational capacity + labor management: same-store growth “over 1%” but “a little lighter” than normal; attributed to some markets with staffing tightness and cost control pressure
  • AI/automation deployment: ambient listening, AI-driven assist for clinical documentation rolled out to “front end” of clinicians; also semi-virtualized front desk approach to reduce front desk FTE needs (labor challenge)

AI IconMarket Outlook

  • Seasonality: June visits averaged 32.3; slight taper expected in summer months before rebounding mid-August
  • Full-year 2025 adjusted EBITDA guidance: $93M–$97M
  • De novos: management expects “probably the strongest de novo year” since CEO joined; recruiting/residency adjustments to support ramp; no expectation of de novo opening impact from capacity constraints

AI IconRisks & Headwinds

  • Medicare headwinds: 2.9% rate reduction; stacked Medicare cuts impact ~ $25M straight off profit line; $5M–$6M YoY headwind quantified
  • Payer pressure: Michigan largest payer policy change effective April 1 negatively impacted net rate
  • Staffing tightness in some markets causing same-store growth to be “a little lighter than everybody expected” (still >1%)
  • Turnover/capacity risk acknowledged: front desk FTEs remain a labor challenge; clinician retention said to be best in ~7 years but no specific turnover rate provided in-session
  • Regulatory uncertainty: proposed 2026 PFS changes described as complicated/knob-turning; CMS methodology issues noted; final ruling expected in December (company cited preliminary estimates)

Sentiment: MIXED

Note: This summary was synthesized by AI from the USPH Q4 2025 (transcript discusses Q2 2025 results) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (USPH)

© 2026 Stock Market Info — U.S. Physical Therapy, Inc. (USPH) Financial Profile